10
Participants
Start Date
January 31, 2010
Primary Completion Date
July 31, 2012
Study Completion Date
August 31, 2013
Lenalidomide plus dexamethasone
Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
Hôpital Michallon, Grenoble
Institut de Cancerologie de la Loire, Saint-Priest-en-Jarez
CHU de Clermont-Ferrand, Clermont-Ferrand
Hôpital Edouard Herriot, Lyon
Collaborators (1)
Celgene Corporation
INDUSTRY
Institut de Cancérologie de la Loire
OTHER